公司独立董事已召开专门会议审议本议案，过半数独立董事同意将本议案提交董事会审议，具体内容详 见同日刊载于巨潮资讯网（http://www.cninfo.com.cn）的《关于控股股东变更同业竞争承诺期限的公 告》。 登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：000566 证券简称：海南海药 公告编号：2026-008 海南海药股份有限公司 第十一届董事会第三十一次会议决议公告 本公司董事会及全体董事保证公告内容的真实、准确和完整，没有虚假记载、误导性陈述或者重大遗 漏。 海南海药股份有限公司（以下简称"公司"） 第十一届董事会第三十一次会议于2026年2月25日以通讯表 决方式召开。本次会议于2026年2月8日以电子邮件等方式送达了会议通知及文件。会议应到董事9人， 实到董事9人，会议的召开符合《公司法》和《公司章程》有关规定。经与会董事认真审议，表决通过 了如下议案： 一、审议通过《关于新兴际华集团和医药控股变更同业竞争履行期限的议案》 新兴际华集团有限公司及新兴际华医药控股有限公司变更同业竞争相关承诺的事项，不违反《上市公司 监管指引第4号一一上市公司及其相关方承诺》及其他相关法律法规的 ...

Core Viewpoint - AstraZeneca's drug Imfinzi (durvalumab) has been approved by China's National Medical Products Administration (NMPA) for first-line treatment of adult patients with mismatch repair deficient (dMMR) advanced or recurrent endometrial cancer, in combination with carboplatin and paclitaxel, followed by monotherapy maintenance [1]. Group 1: Drug Approval and Mechanism - Imfinzi is a humanized PD-L1 monoclonal antibody that binds to the PD-L1 protein, blocking its interaction with PD-1 and CD80, thereby preventing tumor immune evasion and restoring suppressed immune responses [1]. - The approval in China is based on subgroup analysis results from the DUO-E Phase III trial, which is a three-arm, randomized, double-blind, placebo-controlled, multicenter study [1]. Group 2: Clinical Trial Results - In the trial, the combination of durvalumab with carboplatin and paclitaxel, followed by durvalumab monotherapy maintenance, reduced the risk of disease progression or death by 58% compared to the control group [2]. - The median progression-free survival (PFS) for the durvalumab group has not yet been reached, while the median PFS for the control group is 7.0 months [2]. Group 3: Safety Profile - The overall safety and tolerability of the durvalumab combination therapy are good, consistent with previous clinical trial results, and no new safety signals have been reported [2].

Core Viewpoint - The research team from East China University of Science and Technology has developed a non-natural oxidase toolbox for the selective oxidation of taxanes, which lays a solid foundation for the efficient synthesis of paclitaxel and its analogs [2][4]. Summary by Sections Research Development - The study published in Nature Communications focuses on designing an oxidase toolbox that enables site-directed oxidation at multiple positions (C-4, C-6, C-10, C-11, C-12, and C-13) of the taxane skeleton, resulting in the efficient synthesis of 11 new taxane structures [2][4]. - The research addresses the bottleneck in the biosynthesis of paclitaxel, which has been hindered by the low catalytic efficiency and poor expression of natural P450 enzymes responsible for multi-site oxidation [4][5]. Methodology - The team screened 29 types of fungal peroxidases and found that the non-specific peroxygenase TteUPO from Thielavia terrestris exhibited the highest oxidation activity towards taxadiene [4][5]. - The crystal structure of TteUPO was analyzed, leading to the redesign of the enzyme's substrate channel, which improved catalytic efficiency and expanded oxidation sites [5]. Outcomes - A toolbox containing seven key mutants was constructed, allowing for high regio- and stereoselective oxidation at six different sites on the taxane skeleton [5]. - This toolbox not only shows excellent catalytic performance for taxadiene but also for various higher oxidation state taxane derivatives, providing a rich set of enzymatic tools for the green biosynthesis of complex natural products like paclitaxel [5].

Core Viewpoint - The Shandong Economic Development Zone aims to enhance its economic quality and efficiency by focusing on a "3+1" industrial system, which includes new materials, health food and medicine, intelligent manufacturing, and new energy, while implementing a collaborative reform across five chains: industrial, innovation, service, funding, and talent [1] Group 1: Strengthening Resilient Industrial Chains - The development plan addresses issues of scattered industrial layout and weak chain connections by implementing a "three closed-loop, two agglomeration, one leading" strategy to eliminate industrial bottlenecks [2] - A closed-loop system for the silicon materials industry is being established, involving major enterprises and creating a comprehensive supply chain from silicon ore to glass products, targeting a hundred billion-level industry [2] - The molybdenum materials industry is also being upgraded through a closed-loop system, enhancing the production of high-end molybdenum products [2] - The traditional Chinese medicine industry is being developed into a full production process chain, promoting local medicinal materials and establishing a strong brand [2] Group 2: Activating Forward-looking Innovation Chains - The focus is on collaborative innovation through platforms, talent acquisition, and effective transformation to address resource dispersion and talent shortages [4] - Innovation resources are being centralized through the establishment of technology platforms and research centers, leading to significant advancements in key technologies [4] - A talent matching model is being implemented to align skilled personnel with industry needs, resulting in the creation of specialized teams to tackle technical challenges [4] - A closed-loop mechanism for innovation is being established to ensure that research outcomes meet industry demands, fostering a healthy cycle of technology commercialization [4] Group 3: Enhancing Quality Service Chains - Continuous optimization of the business environment is being pursued through innovative service models that enhance efficiency and reduce costs [6] - A dual-party signing model for joint investment is being implemented to facilitate major projects, alongside a comprehensive support system for new enterprises [6] - Customized services are being offered to reduce operational costs for businesses, including tailored facilities and energy supply solutions [6][7] Group 4: Streamlining Diverse Funding Chains - A multi-channel funding supply system is being constructed to meet the financial needs of enterprises at different development stages [8] - A robust investment strategy is being adopted, with a focus on attracting significant projects and ensuring substantial investments [8] - Financial support mechanisms are being established to facilitate easier access to funding for local enterprises [9] Group 5: Solidifying High-end Talent Chains - A comprehensive talent supply system is being developed to attract, utilize, and retain skilled professionals essential for high-quality industrial development [10] - Innovative personnel management practices are being introduced to enhance talent mobility and collaboration across regions [10] - Platforms for practical training and mentorship are being established to develop young professionals into key contributors [10][11]

Core Viewpoint - Shenzhen leads the nation with 347 enterprises selected in the Ministry of Industry and Information Technology's seventh batch of "specialized, refined, unique, and innovative" small giant enterprises, while Dapeng New District has only 6 such enterprises, indicating a lag in nurturing quality SMEs despite high industrial contribution to GDP [1][5]. Group 1: Dapeng New District Overview - Dapeng New District has fewer enterprises and well-known companies compared to traditional strong districts in Shenzhen, but it possesses high-potential development areas like the Baguang area, which was designated as a key growth zone for Shenzhen's International Biological Valley [2]. - The Baguang area was initiated for substantial construction in early 2016, aiming to become a significant growth engine for the region [2]. Group 2: Current Industrial Landscape - After nearly a decade of development, the Baguang area appears underdeveloped, with many industrial spaces remaining vacant and key projects like the Baguang Cultural Center and Sports Center not yet operational [3][6]. - The first industrial project, Biological Garden, has been operational for three years but has low occupancy rates, with many buildings remaining empty [8][10]. Group 3: Project Delays and Challenges - The Baguang Medical Technology Park, which was expected to be a significant development in the medical device sector, remains largely undeveloped three years after its groundbreaking ceremony, with visible signs of neglect [11][12]. - The Dapeng New District has reported a total of 78 projects in the Baguang area, with 57 completed and 8 under construction, but delays in key projects like the Baguang Industrial Incubator and Innovation and Entrepreneurship Park have been noted, with completion pushed to mid-2026 [18]. Group 4: Government Responses and Future Outlook - The Dapeng New District's Technology and Industrial Information Bureau indicated that the region has only 6 "small giant" enterprises, attributing the low number to the area's focus on tourism and a lack of existing enterprises [14]. - The Dapeng New District's Business Bureau reported the addition of 97 enterprises through investment attraction over the past three years, highlighting efforts in various sectors including biomedicine and low-altitude economy [16].

Core Insights - The article discusses the rising incidence of cancer globally, with nearly 20 million new cases and 9.7 million cancer-related deaths reported in 2022, highlighting cancer as a leading cause of disease-related mortality [3] - Traditional cancer treatments like chemotherapy and radiotherapy have limitations due to their lack of tumor specificity, leading to significant side effects [3] - Targeted drug delivery strategies, particularly Aptamer-Drug Conjugates (ApDC), are emerging as promising alternatives for cancer treatment, allowing for selective delivery of cytotoxic drugs to tumor cells [3][6] Group 1: Research Development - A recent study published in "Signal Transduction and Targeted Therapy" introduced Sgc8c-M, an ApDC developed by linking a potent anti-mitotic agent MMAE with the PTK7 aptamer Sgc8c, aimed at treating cancers that overexpress PTK7 [4][6] - The study demonstrated the potential of Sgc8c-M through comprehensive evaluations from rodents to non-human primates, indicating its promise as a cancer therapy [4][9] Group 2: Mechanism and Efficacy - Sgc8c-M showed effective tumor regression in various PTK7-overexpressing cancer types, outperforming unlinked MMAE, the chemotherapy drug paclitaxel, and a PTK7-targeted antibody-drug conjugate [6][9] - Pharmacokinetic studies in mice revealed rapid accumulation of the drug in tumors while being quickly cleared from plasma and normal tissues, with over 75% of MMAE excreted within 24 hours [7] Group 3: Safety and Tolerability - Toxicokinetic assessments indicated that Sgc8c-M maintained consistent systemic drug exposure without accumulation after repeated dosing, and high therapeutic doses were found to be safe [7] - Further evaluations in non-human primates showed similar pharmacokinetic characteristics and good tolerability, with no significant accumulation observed after multiple doses [7]

Core Viewpoint - Cancer remains a leading cause of death globally, prompting the search for new targeted therapies, particularly antibody-drug conjugates (ADCs) which show promise in delivering chemotherapy directly to cancer cells while minimizing side effects [2][3]. Group 1: Current ADC Limitations - Current ADCs have a drug-to-antibody ratio (DAR) of only 2-8, limiting the range of chemotherapy drugs that can be used, as only highly potent drugs can be selected [2][6]. - The limited DAR means that ADCs cannot utilize a broader spectrum of less potent chemotherapy drugs, which constrains treatment options [6]. Group 2: Introduction of ABC Technology - The newly developed antibody-bottlebrush prodrug conjugates (ABC) offer modular synthesis and a significantly higher DAR, allowing for a wider range of effective payloads, including less potent chemotherapy drugs [3][9]. - ABC technology enables the delivery of hundreds of prodrug molecules via a single antibody, enhancing the customization and diversity of drug combinations [8][9]. Group 3: Experimental Results - In preclinical models, ABCs demonstrated superior efficacy in eliminating tumors compared to traditional ADCs and non-targeted prodrugs, even at very low doses [13][14]. - The study showed that ABCs outperformed FDA-approved ADCs like T-DXd and TDM-1, indicating a potential for enhanced treatment outcomes [14]. Group 4: Future Directions - The research team plans to explore combinations of different chemotherapy drugs with varying mechanisms to improve overall efficacy [14]. - There is potential for using various monoclonal antibodies, as over 100 have been approved, to create new targeted cancer therapies through the ABC platform [14].

Core Viewpoint - The article discusses the limitations of Paclitaxel (PTX) as a chemotherapy drug and highlights recent advancements in drug delivery systems that enhance its efficacy and safety in treating various cancers, particularly triple-negative breast cancer and pancreatic cancer [3][4][5]. Group 1: Limitations of Current Paclitaxel Formulations - Paclitaxel is a powerful chemotherapy drug used for multiple cancers but has significant limitations due to poor solubility, unfavorable pharmacokinetics, and severe side effects [3]. - The FDA has only approved two formulations of Paclitaxel: Taxol and Abraxane. Taxol, while improving solubility, can cause severe allergic reactions due to its excipients, necessitating pre-treatment with antihistamines and steroids [4]. - Abraxane, a nanoparticle formulation, is safer than Taxol but does not significantly improve pharmacokinetics or tumor delivery, leading to suboptimal clinical outcomes [4]. Group 2: Recent Research and Innovations - A research team from the University of Arizona developed a novel sphingolipid-derived Paclitaxel nanovesicle called Paclitaxome, which improves pharmacokinetics and enhances anti-tumor efficacy while reducing bone marrow suppression toxicity in mouse models of metastatic triple-negative breast cancer and pancreatic cancer [6][10]. - The study introduced a functionalized delivery system that incorporates a super pH-sensitive probe and CD47 peptide to enhance tumor penetration and reduce immune system phagocytosis, resulting in improved therapeutic outcomes [10]. - The new Paclitaxel formulation demonstrated superior therapeutic effects compared to previously reported Paclitaxel nanocarriers and has potential applications in other drug delivery systems, such as camptothecin [12].

Investment Rating - The report does not explicitly state an investment rating for the oncology drug industry in China, particularly focusing on ovarian cancer treatments. Core Insights - Ovarian cancer is one of the most common malignant tumors in the female reproductive system in China, ranking third in incidence among gynecological malignancies and first in mortality [6] - The early symptoms of ovarian cancer are often non-specific, leading to late-stage diagnosis and low five-year survival rates, hence it is referred to as the "silent killer" [6] - The report highlights the importance of identifying early symptoms such as abdominal discomfort, loss of appetite, and urinary changes [6] Summary by Sections Ovarian Cancer Overview - Ovarian cancer is a significant health threat to women, with a high mortality rate among gynecological cancers [6] - The most common type is epithelial ovarian cancer, which is prevalent in postmenopausal women [6][11] Treatment Pathways - The standard treatment for ovarian cancer includes surgical intervention and chemotherapy, with specific protocols based on FIGO staging [10][11] - Initial treatment options vary from comprehensive staging surgery to neoadjuvant chemotherapy, depending on the cancer stage [11] Key Drugs in Ovarian Cancer Treatment - The report lists several key drugs used in the treatment of ovarian cancer, including Carboplatin, Paclitaxel, and Bevacizumab, with varying insurance coverage and price ranges [15] - The market for first-line chemotherapy drugs is mature, while alternative treatment options still show growth potential [20] Market Dynamics - As of June 2025, the report indicates that Paclitaxel has the highest market presence among approved ovarian cancer drugs in China, followed closely by Bevacizumab [20] - The report notes that while some drugs have saturated the market, others like liposomal doxorubicin are gradually penetrating due to safety advantages [20] Genetic Risk and Prevention - For high-risk populations, genetic counseling and regular screenings are recommended, particularly for those with a family history of ovarian cancer [24][26] - The report emphasizes the importance of identifying high-risk individuals for early intervention and management [26]

Core Insights - The article highlights the significant contributions of Chinese scholars in the latest issue of the journal Nature, with 12 out of 24 papers authored by them, indicating a strong presence in cutting-edge research [1][25]. Group 1: Research on Health and Medicine - A study from Zhaoquan Wang at the Sloan Kettering Cancer Center reveals that high fructose intake in early life impairs microglial phagocytosis and neurodevelopment, potentially increasing anxiety risk during adolescence [1]. - Research by Yang Wei from the NIH discusses the dynamic assemblies and coordinated reactions involved in non-homologous end joining, providing insights into DNA repair mechanisms [4]. - A paper from Gaoqun Zhang at the Max Planck Institute explores the developmental trajectory and evolutionary origin of thymic mimetic cells, shedding light on immune system development [10]. - A study by Lingjie Sang from the University of Texas Southwestern Medical Center identifies glycosaminoglycan-driven lipoprotein uptake as a key mechanism for cancer cells to resist ferroptosis, suggesting a new target for cancer therapy [11]. Group 2: Innovations in Technology and Materials - Research by Jianmin Liang at Arizona State University presents a fully open AI foundation model for chest radiography, outperforming existing models in detecting rare chest diseases [2][4]. - A study from Jack Chun-Ting Liu at Stanford University discovers genes enabling the biosynthesis of baccatin III, a precursor for the anticancer drug paclitaxel, addressing the challenge of sourcing sufficient quantities from natural plants [3]. - A paper from Jia Liu at Harvard University introduces a flexible neural implant that grows with the brain, promising advancements in treating neurological disorders [5]. - Research from Zheng Guo at the University of Science and Technology of China demonstrates a new method to enhance the lifespan of perovskite light-emitting diodes, achieving brightness over 1.16 million nits and a lifespan exceeding 180,000 hours [7]. Group 3: Environmental and Earth Sciences - A study by Jianghui Du at ETH Zurich challenges traditional views on marine biogeochemistry, indicating that various trace elements in the ocean originate from the seafloor [6]. - Research by Peng Gao at Peking University investigates phonon transport dynamics across interfaces, providing insights for thermal interface engineering [8]. - A paper from Wei-Yu Qian at Leibniz University presents the preparation of a neutral nitrogen allotrope, which could open new opportunities for energy storage concepts [9].